MedTrace Logo

INB03 for the Treatment of Pulmonary Complications From COVID-19

NCT04370236 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2026-05-19

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether XPro1595 can prevent the progression of respiratory complications in COVID19 patients.

Conditions

Interventions

DRUG

INB03

Patients will receive up to two once per week subcutaneous injections of 1mg/kg INB03

DRUG

Placebo

Patients will receive up to two once per week subcutaneous injections of Placebo

Sponsors & Collaborators

  • Inmune Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Raymond Tesi, MD · Inmune Bio, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-21
Primary Completion
2021-10-13
Completion
2021-11-18
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04370236 on ClinicalTrials.gov